Otic Pharma Appoints Gregory J. Flesher as Chief Executive Officer

28-Jul-2015 - USA
Otic Pharma Ltd announced the appointment of Gregory J. Flesher as chief executive officer and member of the company's board of directors.
Mr. Flesher brings more than 20 years of drug development and commercialization experience to Otic Pharma. Most recently he was chief business officer at Avanir Pharmaceuticals, Inc. until its acquisition by Otsuka Pharmaceutical for $3.5 billion earlier in the year. During his tenure at Avanir, Mr. Flesher had responsibility for leading the company's corporate strategy, business development, investor relations, and corporate operations functions. Prior to Avanir, Mr. Flesher held positions at InterMune, Inc., Amgen Inc., and Eli Lilly and Company.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances